This site is intended for healthcare professionals
Guidelines
  • Home
  • /
  • Guidelines
  • /
  • Coagulation and haemorrhagic disorders
  • /
  • Management of cancer-associated disseminated intra...
Guideline

Management of cancer-associated disseminated intravascular coagulation

Read time: 1 mins
Last updated:4th Jan 2015
Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the International Society on Thrombosis and Haemostasis (ISTH)


The pathogenesis of cancer-associated disseminated intravascular coagulation (DIC) is complex and multifactorial. It could present as a spectrum ranging from clinically asymptomatic, but with laboratory markers of coagulation activation, to the extreme cases of therapy?resistant thrombosis or bleeding 1. In this guidance, we try to address some practical considerations for this clinical scenario. This statement will provide clinicians with guidance on how best to manage DIC in patients with cancer and offer expert consensus to help decision?making in challenging situations.

 

Read full guideline